Form 4: Alector Director Altmeyer Receives Stock Options and Restricted Stock Units

Director Mark Altmeyer of Alector, Inc. acquired stock options and restricted stock units (RSUs) on March 19, 2024.

Summary

• On March 19, 2024, Mark Altmeyer, a director of Alector, Inc., acquired 41,250 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs vest in 12 equal quarterly installments starting September 1, 2024.
• Altmeyer also acquired options to purchase 19,420 shares of common stock at an exercise price of $6.20.
• These options vest in 48 equal monthly installments beginning on April 19, 2024.
• Following these transactions, Altmeyer directly owns 41,250 shares of common stock and has options for 19,420 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock options and RSU grants to a director, which is a common practice. There are no explicit positive or negative implications for the company's performance.

Positives

• The granting of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedules of the RSUs and stock options suggest a long-term commitment from the director.

Industry Context

Stock options and RSUs are common forms of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry, to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry, often used to attract and retain talent.
• Vesting schedules, like the ones described in the document, are typical for equity compensation, encouraging long-term commitment.
• Comparing Alector's equity compensation practices to companies like Biogen, Amgen, or Genentech would provide a broader context, but this document lacks the necessary details for a comprehensive comparison.

Stakeholder Impact

• The granting of equity to a director can align their interests with shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates